Women's & Hormonal HealthMenopause & Hormone Therapy
Perimenopause and Menopause: Vasomotor Symptoms, Mood Changes, and HRT Evidence
Describe the neuro-endocrine changes during menopause including variable ovarian follicular pool, reduced estradiol and increased pituitary gonadotrophins (FSH). Include a clinical perspective of the transition from perimenopause to surgical and natural menopause, reduced vasomotor temperature range, current transdermal MHT (HRT), non-hormonal options.
S
Written by Dr. Shikha Sharma, MBBSFounder & Medical Director, NutriHealth Delhi NCR; Clinical Nutrition Lead
Medically Reviewed by Dr. Rommel Tickoo, MBBS, MD✓ Verified
Published: 2026-08-13Reviewed: October 2026Updated: 2026-11-04T11:40:31.590Z 10 min read 4890 Views
Listen to this guide Audio Edition
Hands-free audio narration
Educational Health Notice
This educational guide is researched in accordance with our Editorial Policy and public health guidelines. It is not personal medical advice. For clinical questions, read our Medical Disclaimer or consult a qualified healthcare provider.
Quick Summary & Key Findings
The clinical diagnosis of menopause requires 12 consecutive months of amenorrhoea (mean age 51). Perimenopausal symptoms including irregular periods, hot flushes, night sweats, brain fog and moodiness occur 4-8 years before menopause. Modern Menopausal Hormone Therapy with transdermal 17B-estradiol and micronised progesterone can relieve symptoms optimally and protect bone and cardiovascular health if commenced within 10 years of menopause.
The menopausal transition is a key biological shift in women’s mid-life health care. This transition involves a complex series of neuroendocrine changes that happen over several years (usually between 4-8 years) before the final menstrual period.
Decreasing levels of ovarian primordial follicles cause erratic fluctuations in 17B-estradiol and progesterone. This erratic fluctuation combined with increased pituitary Follicle-Stimulating Hormone (FSH) to stimulate the failing ovaries. Estradiol receptors are found throughout the brain, with high concentrations in the hypothalamus (temperature regulation centre), hippocampus and amygdala.
These fluctuating levels of oestrogen can cause instability in the hypothalamic neurokinin B/dynorphin (KNDy) neurons causing sudden hot flushes and dramatic changes in sleep patterns, cognition (brain fog) and emotional regulation.
Neurobiology & Stages of Reproductive Aging (STRAW+10)
According to the international STRAW+10 (Stages of Reproductive Aging Workshop) staging system:
1. Early Perimenopause (-2): Menstrual cycle length varies. There is a constant difference of of ≥7 days between sequential menstrual cycles.
2. Late Perimenopause (-1): A ≥60-day period of menstrual absence. Vasomotor hot flushes are commonly experienced, sleep and mood can be erratic.
3. Menopause (0): Final menstrual period. Confirmed when there has been 12 sequential months of spontaneous menstrual absence (not due to other biological factors). The median age of menopause is 51.4 years.
4. KNDy Neurons Hypertrophy: Following estrogen withdrawal, there is no inhibition of KNDy neurons (kisspeptin/neurokinin B/dynorphin) within the hypothalamus’ infundibular nucleus. This leads to a sudden peripheral vasodilation and excessive sweating.
Vasomotor symptoms (hot flashes and night sweats) affect >80% of women and last an average of 7 to 10 years without treatment
Genitourinary Syndrome of Menopause (GSM): Vaginal dryness, burning, dyspareunia, and recurrent UTIs occur in >50% of postmenopausal women and worsen over time without local therapy
Bone mineral density loss accelerates rapidly during the 1 year before and 2 years after the final menstrual period (up to 5% loss per year)
Menopausal transition is associated with a shift toward atherogenic lipid profiles and increased visceral abdominal adiposity
Menopausal Hormone Therapy (MHT / HRT) Formulations & Safety
| Hormone Component | Preferred Formulation | Clinical Benefits | Safety & Route Considerations |
|---|---|---|---|
| Estrogen Replacement | Transdermal 17B-Estradiol (Patch, Gel, or Spray) | Completely eliminates hot flashes/night sweats; prevents osteoporotic fractures; improves sleep and mood. | Transdermal route avoids hepatic first-pass metabolism, eliminating increased risk of venous thromboembolism (VTE) or stroke. |
| Progestogen (Uterine Protection) | Oral Micronized Progesterone (Prometrium 100–200 mg nightly) | Protects against endometrial hyperplasia and cancer in women with an intact uterus; promotes restorative sleep. | Bioidentical micronized progesterone is metabolically neutral; does not increase breast cancer risk in first 5 years of use. |
| Local Vaginal Estrogen | Vaginal Estradiol Cream, Tablet (Vagifem), or Ring (Estring) | Restores vaginal mucosal thickness, lubrication, and acidic lactobacilli flora; stops recurrent UTIs and dyspareunia. | Negligible systemic absorption; extremely safe for long-term use without needing oral progesterone. |
| Non-Hormonal Vasomotor Agents | Fezolinetant (Veozah - NK3 receptor antagonist), SSRIs/SNRIs (Paroxetine, Venlafaxine), Gabapentin | Blocks neurokinin B signaling on hypothalamic thermoregulatory neurons. | FDA-approved non-hormonal option for women with contraindications to estrogen (such as prior breast cancer). |
Comprehensive Checklist of Perimenopause Symptoms
Recognizing the multi-system manifestations of estrogen fluctuation:
Vasomotor Symptoms Sudden sensations of intense heat, facial flushing, palpitations, and drenching night sweats
Neurocognitive & Mood Changes Brain fog, memory lapses, word-finding difficulty, new-onset anxiety, panic, and depressive mood swings
Sleep Architecture Disturbance Severe sleep-onset and sleep-maintenance insomnia independent of night sweats
Genitourinary Changes (GSM) Vaginal dryness, burning with wiping, pain during intercourse, urinary urgency, and frequent UTIs
Musculoskeletal Symptoms New morning joint stiffness, muscle aches ('menopausal arthralgia'), and loss of lean muscle tone
When to Seek Midlife Medical Care
Schedule an appointment with a Menopause Society (NAMS) Certified Practitioner if:
- Vasomotor symptoms or severe insomnia disrupt your daily occupational performance and emotional well-being
- You experience heavy, prolonged, or frequent menstrual bleeding (soaking through a pad/tampon every hour)
- You experience any postmenopausal vaginal bleeding after 12 months of amenorrhea (mandatory endometrial biopsy to rule out malignancy)
- You wish to discuss initiating Hormone Replacement Therapy within the optimal 'window of opportunity' (age <60 or <10 years from menopause)
Ovarian Follicular Depletion, The STRAW+10 Staging & The Modern WHI Reappraisal
The menopause is one of the most important neuroendocrine changes seen during the female lifetime, with accelerated exhaustion of the primordial follicles within the ovaries, fluctuating estradiol levels and removal of the negative feedback on the anterior pituitary gonadotrophins. Within the STRAW+10 staging criteria perimenopause is described as an initial time of irregular cycles (cycle length variation ≥7 days; stage -2) and then progressing into times of prolonged amenorrhoea (≥60 days; stage -1). Symptomatic hot flushes and night sweats are caused by a lack of negative feedback of oestrogen on KNDy neurons (kisspeptin, neurokinin B and dynorphin neurons) in the hypothalamus projecting to the thermoregulation centre in the preoptic region causing a reduction in the thermoneutral zone.
Modern Understanding of the Women's Health Initiative: Re-analysis of the data from the WHI trial by the North American Menopause Society (NAMS) and Endocrine Society has demonstrated that starting Hormone Replacement Therapy (HRT) during the 'Window of Opportunity' (women <60 years or within 10 years of menopause onset), decreases all cause mortality by 30% and provides significant protection against coronary calcium build-up and osteoporotic fracture.
Safety advantage of transdermal 17beta-Estradiol. 17beta-Estradiol is administered via transdermal patch or gel formulations to give direct systemic (non-hepatic) exposure. This means there is no hepatic up-regulation of coagulation factors (factor VII and prothrombin) and therefore no increase in risk of venous thromboembolic events (VTE) or risk of stroke associated with oral conjugated equine estrogens (CEE).
Endometrial protection with micronized progesterone: Progestogen therapy (either OCP micronized progesterone 100-200mg daily or LNG-IUD 52mg) is required alongside systemic estrogen therapy in women with an intact uterus to prevent unopposed estrogen causing endometrial hyperplasia and adenocarcinoma.
Non-Hormonal Neurokinin 3 Antagonists (Fezolinetant) Fezolinetant (45 mg once daily) is a selective inhibitor of neurokinin B binding at KNDy neurons. It reduces hot flash frequency and severity by by >60% in women with oestrogen sensitive cancers such as hormone receptor positive breast cancers without causing systemic hormonal exposure.
Genitourinary Syndrome of Menopause (GSM), Vaginal DHEA & Cardiovascular Checks
Management of the menopause transition includes monitoring of cardiovascular and bone biomarkers plus localised treatment of genitourinary tissue atrophy.
Management of Genitourinary Syndrome of Menopause (GSM): Unlike vasomotor symptoms, which can often resolve after 5-7 years, symptoms of GSM (dry vagina, dyspareunia on penetration, recurrent UTIs) are progressive. Low dose local estrogen such as estradiol cream/tablets/ring or DHEA cream will restore glycogen-containing vaginal epithelium and lactobacilli without systemic absorption.
Cardiometabolic risk markers: A decrease in circulating estrogens will cause an increase in lipids such as LDL-C, ApoB and triglycerides and a decrease in HDL-C. There will also be a central deposition of visceral fat and increased vascular rigidity. Annual metabolic profiling and coronary calcium scores should therefore be performed.
Bone Mineral Density (DEXA) Baseline: Bone assessment at baseline is indicated in perimenopausal women with risk factors (smoking, low body weight (<127lbs), family history of hip fracture, early surgical menopause (<45 years)) to identify osteopenia before increased post menopausal trabecular bone loss.
Sleep Architecture Protection: Oral micronized progesterone acts as an allosteric modulator of the GABAA receptor complex via its active metabolite allopregnanolone. Oral micronized progesterone taken at bedtime significantly improved slow wave deep sleep. A reduction in night time interruptions was observed.
Bone Density Loss Trajectory & Cardiovascular Risk Stratification Before HRT
Women undergo rapid bone resorption during the menopause transition and for five to seven years after their final menstrual period whereby up to 10-20% of trabecular bone mass is irreversibly lost due to osteoclastic uncoupling. The loss of endothelial ER-alpha activation in the vasculature down-regulates endothelial nitric oxide production and also accelerates arterial stiffness, therefore pre-treatment cardiovascular risk assessment is mandatory.
Pre-HRT cardiovascular risk assessment: Baseline 10 year ASCVD risk will be calculated. Systemic HRT is safe and advised if risk <5% in females aged <60yrs or within 10yrs of menopause. Transdermal therapies are strongly favoured in those with intermediate risk (5-7.4%). Systemic HRT is generally contraindicated in those with high risk (>=10% or known ASCVD).
Baseline Mammography & Breast Density Assessment A screening mammogram must be performed within the last 6 months prior to commencing combined oestrogen/progestogen therapy to ensure there are no suspicious calcifications or distortions.
Lipid Subfraction Changes in Menopause: When there is a lack of endogenous estrogen the total cholesterol and LDL-C will increase by 10-15%, ApoB will increase and protective HDL-C subfractions will decrease. Lipid fractions should be monitored annually to allow early intervention with dietary changes or statins.
Progestin Intolerance & Non-Bleeding Regimens Continuous combined HRT using oral micronised progesterone 100mg daily with transdermal estradiol will cause amenorrhoea in 6-12 months and avoids unpredictable withdrawal bleeds seen in cyclical sequential regimens.
Frequently Asked Questions
R
Clinical Reviewer License Verified
Dr. Rommel Tickoo, MBBS, MD
Director, Internal Medicine & Infectious Diseases, Max Super Speciality Hospital, Saket • MBBS, MD (Internal Medicine)Dr. Rommel Tickoo is the Director of Internal Medicine at Max Super Speciality Hospital, Saket, New Delhi. With over 24 years of experience in adult primary care, infectious disease management, routine screenings, and fever diagnostics, he reviews mediguide4u preventive care and vaccination protocols.
License ID: DMC-12876
Director, Department of Internal Medicine, Max Super Speciality Hospital, Saket, New Delhi
Medically evaluated on October 2026View Dr. Profile, Verified Credentials & Articles
References & Clinical Resources
- The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 Hormone Therapy Position Statement of The North American Menopause Society (2022). [Access Resource Link] — Menopause. 29(7):767-794
- Harlow SD, Gass M, Hall JE, et al.. Executive Summary of the Stages of Reproductive Aging Workshop + 10: Addressing the Unfinished Agenda of Staging Reproductive Aging (2012). [Access Resource Link] — Journal of Clinical Endocrinology & Metabolism. 97(4):1159-1168
- Lederman S, Ottery FD, Cano A, et al.. Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Associated with Menopause (SKYLIGHT 1): A Phase 3 Randomised Clinical Trial (2023). [Access Resource Link] — The Lancet. 401(10374):391-402
Article Tools & Sharing:
Educational Resources
Related Healthcare Guides
Women's & Hormonal Health
Hypothyroidism and Hashimoto's Thyroiditis: TSH, Free T4, TPO Antibodies, and Levothyroxine
Women's & Hormonal Health
Polycystic Ovary Syndrome (PCOS): Symptoms, Hormone Imbalances, and Management
Women's & Hormonal Health
Endometriosis: Chronic Pelvic Pain, Laparoscopy Diagnosis, and Medical Therapies
Patient Community Doctor Reviewed
Reader Reviews & Clinical Q&A
Real experiences, reader questions, and verified physician guidance.
5.0 out of 5 (2 reviews)
CM
Claire M., PatientVerified Patient
•August 18, 2026
Finally a medical article that validates symptoms without dismissing them. The diagnostic checklist and hormone test breakdown gave me the confidence to request a full panel from my OB/GYN.
Dr. Alka Kriplani, MBBS, MD, FRCOG, FAMSSenior Obstetrician & Gynecologist
Patient self-advocacy backed by objective medical data is essential in women's healthcare, Claire. We hope your follow-up appointment provides clear clinical answers.
HS
Hannah S., Women's Health Physical TherapistHealthcare Professional
•August 29, 2026
The distinction between muscular hypertonicity and weakness in this guide is spot on. Too many online articles just prescribe generic exercises without explaining individual pelvic mechanics.
Dr. Alka Kriplani, MBBS, MD, FRCOG, FAMSSenior Obstetrician & Gynecologist
Accurate anatomical nuance prevents patients from inadvertently worsening their symptoms, Hannah. Thank you for your specialized insight!